Analysts/Institutional Investor Meet/Con. Call Updates

cfrancec/ enzymes WhoreENZYMEisLife AdvancedEnzymeTechnologiesLtd. CIN:L24200MH1989PLC051018 SunMagnetica,Awing,5thFloor,LICServiceRoad,Louiswadi,Thane(W)-400604,India Tel:+91-22-41703200,Fax:+91-22-25835159 Email:info@advancedenzvmes. com, www.advancedenzymes. August 18, 2026 BSE Limited National Stock Exchange of India Ltd. Department of Corporate Affairs Exchange Plaza, Plot No. C/1, G Block P. J. Towers, Dalal Street, Bandra-Kurla Complex, Bandra (E) Mumbai- 400 001 Mumbai- 400 051 Scrip ID-540025 Scrip Code-ADVENZYMES Dear Sir/Madam, Sub: Transcript of Conference call held on August 12, 2026 for the Unaudited Financial Results for the quarter ended June 30, 2026. In furtherance to our intimation letter dated August 04, 2026, please find enclosed herewith the Transcript of the Conference call held on Wednesday, August 12, 2026 with Analysts and Investors for the Unaudited Financial Results of the Company for the quarter ended June 30, 2026. The aforesaid information is also being uploaded on the website of the Company. Kindly take same on your records. Thanking you, Yours Faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head - Legal Encl.: As above Factory:PlotNo.A-61/62,MIDCMalegaon,Tal.Sinnar,Dist.Nashik-422113.Maharashtra.India.Tel.:+91-9970100750/+91-2551-230044,Fax:+91-2551-230816 ttoanced enzymes WhereENZYMEisLife “Advanced Enzyme Technologies Limited Q1 FY '27 Earnings Conference Call” August 12, 2026 Management: Mr. Mukund Kabra – Whole Time Director Mr. Beni Rauka – Group Chief Financial Officer Mr. Ronak Saraf – Investor Relations Manager Disclaimer: This is a transcription and may contain transcription errors. The transcript has been edited for clarity, readability, etc. The Company takes no responsibility of such errors, although an effort has been made to ensure high level of accuracy. Kindly Note, there could be unpublished price sensitive information that would have been shared /discussed during the call. Complying with the SEBI regulations, we have shared Audio Transcript to the Stock Exchanges and the Company website on August 12, 2026 for information of public at large. Page 1 of 19 Moderator Good afternoon, ladies and gentlemen. I'm Akash, moderator for the conference call. Welcome to Advanced Enzyme Technologies Limited Q1 FY27 Earnings Conference Call. As a reminder, all participants will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing * and 0 on your touch-tone telephone. Please note this conference is being recorded. I would now like to hand over the floor to Mr. Ronak Saraf. Thank you, and over to you, sir. Ronak Saraf Welcome to the Advanced Enzyme Technologies Q1 FY27 earnings conference call. We hope you all have gone through our financials, press release and the presentation which has been posted in the investor relations section of our website. We have with us Mr. Mukund Kabra, Whole-time Director and Mr. Beni Rauka, Group Chief Financial Officer. Today, the management will discuss the performance & business highlights, update on strategies and respond to any questions that you may have. As is usual, for ease of discussion we will look at the consolidated financials. I would like to draw your attention to the fact that some of the information shared during this call—particularly regarding our plans, strategies, and future outlook—may contain forward-looking statements. These statements involve inherent risks and uncertainties and are based on current expectations, forecasts, and assumptions. Actual results may differ materially from those expressed or implied in these statements, influenced by a range of factors including but not limited to economic conditions, changes in government policies, regulatory developments, and other unforeseen circumstances. Recipients are cautioned not to place undue reliance on these forward-looking statements, as they are not guarantees of future performance and should not be viewed as a substitute for independent judgment. The Company undertakes no obligation to update or revise any such statements, whether as a result of new information, future events, or otherwise. So, without any further ado we shall commence this call. Over to you Mukund Sir. Mukund Kabra Thank you, Ronak. Good evening, everyone. Thank you for joining us today for our Q1 FY27 Earnings Call. I extend a warm welcome to all our shareholders and partners. The global economy has been experiencing significant disturbance for quite some time, primarily driven by geographical tensions, trade and uncertainties, and continued disruption across global supply chain. These challenges have had a direct impact on the pricing of energy and certain raw materials, creating a volatile operating environment for businesses globally. Against this backdrop, our Q1 performance reflects a softer, more muted start to the fiscal year. However, the fundamental strength of our business remains firmly intact, and we anticipate progressive momentum as the year advances. While it is important to view this performance in the context of the inherent nature of our business, that's the reason we always suggest all our shareholders to evaluate our business on an annual horizon rather than through the length of a single quarter. Our top line for the quarter stood at INR 1,898 million, registering a 2% YoY growth. On a sequential basis, revenue declined by 7% compared to the previous quarter. As part of the standard revenue recognition practices, which is based on transferring of control of goods to the customers, sales reversal occurs every quarter. On account of revenue recognition accounting principles, this quarter was impacted by an additional sales reversal amounting to INR 100 million over and above reversal of revenue generally being accounted in every quarter. I'm pleased to share that this revenue reversal has already been recorded as of today, maintaining the robustness of our revenue pipeline intact. Our fundamentals remain strong, execution continues to be solid, and we are well positioned to capitalize on growth opportunities. We remain confident in delivering sustainable revenue growth consistent with our annual guidance. Page 2 of 19 EBITDA for the quarter came in at INR 510 million, down 10% YoY and 19% QoQ. Consequently, the EBITDA margin stood at 27% compared to 30% in Q1 FY26 and 31% in Q4 FY26. Our consolidated margins moderated primarily due to three factors: lower top-line realization, elevated power and fuel costs driven by global energy disruption, and a temporary shift in the sales mix. But at the same time, our disciplined focus on optimizing our costs and improve our operational efficiencies position us to deliver sustainable growth and stronger performance as the year progresses. Moving to profitability, profit after tax stood at INR 386 million declining 5% YoY and 15% sequentially. The PAT margin for the quarter was 20% compared to 22% in both Q1 FY26 and Q4 FY26. Now, I will take you through our segment-wise revenue performance for the Q1 FY27 and compare it both YoY and sequentially with Q4 FY26 and Q1 FY26. Let's begin with Human Healthcare: Revenues from Q1 FY27 stood at INR 1,139 million, reflecting a 7% YoY decline and 11% sequential decline. The decline was primarily attributed to lower sales in the Pharma API business. Despite the moderation of revenues, the segment contributed 60% of total revenue during the quarter. We observed an improvement in our B2C revenue in USA. Moving to Animal Healthcare: Revenue stood at INR 252 million, registering a 3% YoY decline while growing 1% QoQ. The segment contributed 13% to our overall revenue during the quarter. Turning to Bioprocessing, the segment reported revenues of INR 306 million, delivering 30% YoY growth. Revenues were 5% lower sequentially. The strong YoY perfor [Showing first 8,000 characters — download PDF for full document]